Kyverna Therapeutics (NASDAQ:KYTX) Shares Gap Up – Should You Buy?

Kyverna Therapeutics, Inc. (NASDAQ:KYTX)’s share price gapped up before the market opened on Wednesday . The stock had previously closed at $9.71, but opened at $11.08. Kyverna Therapeutics shares last traded at $9.1940, with a volume of 2,578,562 shares.

More Kyverna Therapeutics News

Here are the key news stories impacting Kyverna Therapeutics this week:

• Positive Sentiment: Registrational Phase 2 KYSA-8 met primary and all secondary endpoints in stiff person syndrome (SPS): a single dose produced rapid, statistically significant and durable improvements in walking speed, disability and stiffness; all 26 patients discontinued chronic immunotherapies and safety was manageable. This is the company’s most consequential clinical readout and supports a potential first‑in‑class approval pathway. GlobeNewswire release
• Positive Sentiment: Market reaction: premarket coverage and headlines are pushing the stock higher as investors price in the commercial and regulatory upside from a registrational win and the prospect of a Biologics License Application (BLA). MarketWatch article
• Positive Sentiment: Company and analysts are framing this as a platform opportunity beyond SPS (gMG and other B‑cell neurologic autoimmune diseases); Kyverna said it is preparing a BLA and will discuss updated gMG data on a conference call. Positive analyst commentary and some upgraded/strengthened ratings followed the data. TipRanks release
• Neutral Sentiment: Investor event: Kyverna hosted a conference call and presentations at AAN to walk through KYSA-8 and gMG data; management highlighted durability, exploratory biomarker changes (GAD65 reductions) and outpatient tolerability potential. Listen for regulatory timing and planned next steps. Business Insider summary
• Negative Sentiment: Small, uncontrolled trial and execution risk: the KYSA-8 readout is from 26 patients in a single‑arm study — critics and some analysts warn results may not generalize, regulators could request additional data, and the program faces manufacturing, reimbursement and commercial execution risks. Seeking Alpha analysis
• Negative Sentiment: Safety and follow‑up considerations: while no high‑grade CRS/ICANS were reported, there were Grade 3/4 neutropenia events and three serious treatment‑related AEs (all resolved). Regulators will scrutinize safety and durability in labeling and post‑marketing commitments. QuiverQuant summary

Analyst Ratings Changes

KYTX has been the topic of a number of research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kyverna Therapeutics in a research report on Friday, March 27th. Wall Street Zen cut Kyverna Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $28.67.

Kyverna Therapeutics Trading Down 4.7%

The company has a current ratio of 7.75, a quick ratio of 7.75 and a debt-to-equity ratio of 0.11. The stock has a market capitalization of $560.21 million, a price-to-earnings ratio of -2.54 and a beta of 2.62. The firm has a 50-day moving average of $8.53 and a 200 day moving average of $8.09.

Kyverna Therapeutics (NASDAQ:KYTX) last posted its earnings results on Thursday, March 26th. The company reported ($0.80) EPS for the quarter, meeting the consensus estimate of ($0.80). As a group, equities analysts predict that Kyverna Therapeutics, Inc. will post -3.24 EPS for the current fiscal year.

Hedge Funds Weigh In On Kyverna Therapeutics

Hedge funds have recently modified their holdings of the company. Ameriprise Financial Inc. acquired a new position in shares of Kyverna Therapeutics during the 3rd quarter valued at $77,000. Rhumbline Advisers increased its position in shares of Kyverna Therapeutics by 22.0% during the 1st quarter. Rhumbline Advisers now owns 31,614 shares of the company’s stock valued at $61,000 after purchasing an additional 5,694 shares during the period. Public Employees Retirement System of Ohio acquired a new position in shares of Kyverna Therapeutics during the 3rd quarter valued at $28,000. Banque Cantonale Vaudoise bought a new stake in shares of Kyverna Therapeutics during the 1st quarter worth $263,000. Finally, Wesbanco Bank Inc. bought a new stake in shares of Kyverna Therapeutics during the 1st quarter worth $952,000. 18.08% of the stock is currently owned by institutional investors and hedge funds.

About Kyverna Therapeutics

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.